Endocrine therapy (ET) is a standard treatment to target hormone receptor-positive (HR+) neoplastic growths in people with HR+ breast cancer, and is typically prescribed for five to ten consecutive years [1]. This evidence concerns the gene NR4A1 and breast cancer.